Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens

Eugene E. Wright,Jr.,Carol H Wysham,Richard M Bergenstal

DOI: https://doi.org/10.1089/dia.2024.0107

2024-05-18

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism

What problem does this paper attempt to address?

Standardizing Reporting of Glucose and Insulin Data for Patients on Multiple Daily Injections Using Connected Insulin Pens and Continuous Glucose Monitoring

David Rodbard,Satish K Garg

DOI: https://doi.org/10.1089/dia.2021.0030

Abstract:Background: Recent development and availability of several connected insulin pens with digital memory are likely to expand the availability of glucose and insulin metrics that previously had been available only for the much smaller number of people using insulin pumps. It would be highly desirable to standardize data presentations to avoid the chaotic emergence of multiple formats that might reduce the clinical utility of connected pens. Methods: We reviewed the literature and analyzed data displays from multiple blood glucose monitoring, continuous glucose monitoring (CGM), insulin pump, and automated insulin delivery systems, and methods for combination of glucose and insulin data. We examined multiple forms of presentation and now propose a prototype for a standardized method for data analysis and display, focusing on the content and format of a one-page dashboard summary for patients on multiple daily injection (MDI) insulin regimens. Results: We propose the following metrics to be included in the one-page report: (A) glucose metrics: simplified glucose distribution in the form of a stacked bar chart showing percentages of time below-, above-, or within-target ranges overall and (optionally) by date, by time of day, or day of the week; (B) insulin metrics: types and doses, and timing of basal and bolus insulin; (C) an enhanced ambulatory glucose profile or "AGP+" showing glucose data points and/or distributions (10th to 90th percentiles), dosages and timing of basal and bolus insulins and (optionally) graphical display of risk of hypoglycemia and hyperglycemia; and (D) user experience regarding technology usage, frequency of alerts for hypo- and hyperglycemia, and information regarding lifestyle, meals, exercise, and sleep, if available; and (E) clinical insights and interpretation. Conclusion: We propose a prototype for a dashboard summary report of glucose, insulin, meals, and activity data intended for providers and patients on MDI using connected pens and CGM. Our goal is to stimulate development of a standardized approach.
Beyond Glucose Monitoring: Multianalyte Sensor Use in Diabetes.

Kathy Zhou,Steven James,Michele Gaca,Ashani Lecamwasam,Muamer Dervisevic,David N O'Neal,Nicolas Voelcker,Elif Ilhan Ekinci

DOI: https://doi.org/10.1089/dia.2024.0250

2024-07-27

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Health literacy of patients using continuous glucose monitoring

Ebony I Evans,Kathleen J Pincus,Hyunuk Seung,Charmaine D Rochester-Eyeguokan

DOI: https://doi.org/10.1016/j.japh.2024.102109

Abstract:Background: Low health literacy and numeracy are associated with poor health outcomes and lower self-efficacy. Continuous glucose monitors (CGMs) can improve diabetes management, but their benefits may be limited by health literacy levels. Objectives: Our objective was to characterize health literacy levels of ambulatory care patients using CGMs to manage their diabetes in 1 urban health system. Secondary aims were to identify specific knowledge deficits related to CGM education and determine predictors of self-rated comfort with and understanding of CGM use. Methods: Participants with type 1 or type 2 diabetes using CGMs were identified using electronic medical records. Participants completed a telephone survey, including the Health Literacy Scale/Subjective Numeracy Scale (HLS/SNS) and an investigator-developed survey assessing CGM comfort and understanding. Descriptive statistics were reported for demographic information. The associations between patient characteristics and survey responses were evaluated using the chi-square test, Fisher's exact test, or Wilcoxon rank-sum test. Results: Eighty-two participants completed the surveys. The median HLS/SNS score for study participants was 80 (Interquartile range 71-89). Associations were found between HLS/SNS scores and education level, reported income, and private insurance coverage. Participants with higher HLS/SNS scores reported higher levels of CGM understanding and comfort. Fifty-one percent of participants (n = 42) reported no or inadequate training prior to CGM initiation. Better A1C results (<8%) were associated with higher self-rated responses in the investigator-developed survey. Conclusion: CGMs should not be withheld from individuals with low health literacy. Incorporating baseline health literacy assessment and offering literacy sensitive training will help optimize the benefits derived from this technology.
Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research

oliver schnell,katharine barnard,richard m bergenstal,emanuele bosi,satish k garg,bruno guerci,thomas haak,irl b hirsch,linong ji,sashank r joshi,maarten c kamp,lori laffel,chantal mathieu,william h polonsky,frank j snoek,p d home

DOI: https://doi.org/10.2337/dc14-2919

2015-01-01

Diabetes Care

Abstract:Free to read Introduction Quality glucose information is a core prerequisite for successful diabetes management. It enables professionals and people with diabetes to make medically relevant decisions on therapy. Details of glucose profile information beyond HbA1c have been largely derived from self-monitoring of blood glucose (SMBG). Given the evidence base demonstrating the benefits of SMBG, its routine use is recommended for diabetes management and therapy by many international and regional guidelines (1–3). Today, SMBG is considered an important aspect of the management of glycemic control (3,4). Glucose information of high quality, considering the products used and the processes conducted, is also needed in clinical research in order to gain new evidence and insights on effective treatment strategies in diabetes. SMBG is widely and routinely applied in large clinical trials, where it is used to understand the glycemic state, to enhance awareness of the effects of lifestyle modification and the adaptation of treatment including insulin titration, and to enable documentation of intraday pre- and postprandial glucose excursions (glycemic variability) and the subsequent statistical analysis of this and the confirmation of hypoglycemic episodes. Examples of recent studies that used SMBG are Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial, Action to Control Cardiovascular Risk in Diabetes (ACCORD), and, from earlier times, the Diabetes Control and Complications Trial (DCCT) (5–8). Indeed, SMBG is now applied in most studies of glucose-lowering agents, including glucagon-like peptide 1 (GLP-1) receptor agonist and sodium–glucose cotransporter 2 (SGLT2) inhibitor studies.
923-P: Benefits of Electronic Consultations (E-Consults) in Improving Diabetes Care within a Safety-Net Health System

FELONA GUNAWAN,SYED AJAZ,LUIGI MENEGHINI,UMA GUNASEKARAN

DOI: https://doi.org/10.2337/db22-923-p

IF: 7.7

2022-06-01

Diabetes

Abstract:Timely access to diabetes specialty care is often limited by resources, especially within a safety-net health system serving a large under/un-insured and ethnically diverse patient population. Implementation of a diabetes electronic consultation (e-consult) service offers several potential benefits, including timely access to diabetes specialists’ input, improvement in patients’ glycemic control, decreased need for in-person referral or visit (a potential benefit to patients and providers) , and an opportunity to support primary care providers with targeted education. We performed a retrospective electronic medical record review of completed diabetes e-consults within a 3-year period (2018-2021) at a large safety-net health system in Dallas, TX to determine the effectiveness of e-consult service. A total of 277 e-consult encounters were completed for 266 patients (age 52.8±12 years, 65% female, 46% Hispanic, 56% Caucasian, 39% Black, 91% with type 2 diabetes) . The average specialist response time following an e-consult request was 2 days, with recommendations fully or partially implemented for 78% of the e-consults. For the 145 patients with reliable hemoglobin A1c (HgbA1c) data at baseline and within 6 months, the HgbA1c improved from an average of 10.1±2.1% to 9.3±1.8% (paired t-test, p=<0.05) , with an average HgbA1c change of -0.7±1.8%. Only 51% of these patients were subsequently referred for in-person diabetes clinic visit. Moreover, review of the e-consults questions helped identify common knowledge gaps in diabetes care among the primary care providers, and led to the development of monthly educational webinar series for primary care providers. In conclusion, implementation of diabetes e-consult service improved timely access to diabetes specialty care as well as patients’ glycemic control, and also created an educational opportunity to improve overall diabetes care within a large safety-net health system. Disclosure F.Gunawan: None. S.Ajaz: None. L.Meneghini: Employee; Sanofi. U.Gunasekaran: None.

endocrinology & metabolism
Response to: MiniMed 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias – Response to Inaccurate Allegations

Gregory P. Forlenza,Jennifer L Sherr

DOI: https://doi.org/10.1089/dia.2024.0125

2024-03-22

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes

Simon Bergford,Michael C. Riddell,Robin Gal,Susana R Patton,Mark A Clements,Jennifer L Sherr,Peter Calhoun

DOI: https://doi.org/10.1089/dia.2024.0061

2024-04-27

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Tadej Battelino,Thomas Danne,Richard M. Bergenstal,Stephanie A. Amiel,Roy Beck,Torben Biester,Emanuele Bosi,Bruce A. Buckingham,William T. Cefalu,Kelly L. Close,Claudio Cobelli,Eyal Dassau,J. Hans DeVries,Kim C. Donaghue,Klemen Dovc,Francis J. Doyle,Satish Garg,George Grunberger,Simon Heller,Lutz Heinemann,Irl B. Hirsch,Roman Hovorka,Weiping Jia,Olga Kordonouri,Boris Kovatchev,Aaron Kowalski,Lori Laffel,Brian Levine,Alexander Mayorov,Chantal Mathieu,Helen R. Murphy,Revital Nimri,Kirsten Nørgaard,Christopher G. Parkin,Eric Renard,David Rodbard,Banshi Saboo,Desmond Schatz,Keaton Stoner,Tatsuiko Urakami,Stuart A. Weinzimer,Moshe Phillip

DOI: https://doi.org/10.2337/dci19-0028

2019-06-08

Diabetes Care

Abstract:Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

endocrinology & metabolism
Monitoring Technologies – Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control

K. Dungan

2014-04-30

Abstract:It is recognized that traditional measures of glucose control (such as hemoglobin A1c [A1C]) provide little information regarding the need for day to day changes in therapies. While intermittent self-monitored blood glucose (SMBG) provides additional information with which to make treatment decisions, significant barriers to its use exist, such as inconvenience and lack of timely and regular feedback. Furthermore, important information regarding glucose trends may be missed. Continuous glucose monitoring (CGM) has become increasingly reliable and has demonstrated efficacy in terms of improving A1C, reducing hypoglycemia, and improving the time in target glucose range. Incremental progress continues to be made toward a fully functional artificial pancreas, of which CGM will play a vital role. As more and more data are presented to patients and providers, it has become increasingly paramount that the data are organized in a standardized way and that communication of data is streamlined using patients’ mobile devices where available and within the existing clinic infrastructure. Systems that provide immediate feedback to patients and decision support tools for patients and providers have demonstrated superior outcomes compared to routine SMBG alone. Alternate markers of glucose control may provide complementary information about glucose control and long-term prognosis. This chapter will review the latest evidence for use of professional and personal CGM, mobile glucose monitoring approaches, and biomarkers of glycemic control. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG .

Medicine
Professional flash continuous glucose monitoring as a supplement to A1C in primary care

Irl B Hirsch

DOI: https://doi.org/10.1080/00325481.2017.1383137

Abstract:Decreasing glycated hemoglobin (A1C) is the primary goal of current diabetes management due to intervention studies in type 1 and type 2 diabetes associating levels <7.0% (53 mmol/mol) with lower complication risk. Strategic self-monitoring of blood glucose (SMBG) is also recommended to achieve greater time in range, with fewer extremes of hypo- or hyperglycemia. Unlike A1C, SMBG can distinguish among fasting, prandial, and postprandial hyperglycemia; uncover glycemic variability, including potentially dangerous hypoglycemia; and provide feedback to patients about the effects of behavior and medication on glycemic control. However, it has the drawback of capturing only static glucose readings and users are often dependent on time-pressed clinicians to interpret numerous data points. A novel flash continuous glucose monitoring (FCGM) device used for a single 2-week period with a readily interpretable data report know as the ambulatory glucose profile (AGP) has the potential to overcome limitations of conventional technologies, with less cost and greater convenience. This review summarizes the rationale for using intermittent FCGM as a supplement to A1C in primary care, and provides a stepwise approach to interpreting the AGP visual display for efficient individualized therapy.
Assessing Patterns of CGM use and Metrics of Glycemic Control in T1D and T2D Patients in the Veterans Healthcare System: Integrating CGM Device Data with EHR Data

Tomoki Okuno,Sharon Macwan,Donald Miller,Gregory Norman,Peter Reaven,Jin Zhou

DOI: https://doi.org/10.1089/dia.2024.0083

2024-05-21

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
International Consensus on Use of Continuous Glucose Monitoring

Thomas Danne,Revital Nimri,Tadej Battelino,Richard M. Bergenstal,Kelly L. Close,J. Hans DeVries,Satish Garg,Lutz Heinemann,Irl Hirsch,Stephanie A. Amiel,Roy Beck,Emanuele Bosi,Bruce Buckingham,Claudio Cobelli,Eyal Dassau,Francis J. Doyle,Simon Heller,Roman Hovorka,Weiping Jia,Tim Jones,Olga Kordonouri,Boris Kovatchev,Aaron Kowalski,Lori Laffel,David Maahs,Helen R. Murphy,Kirsten Nørgaard,Christopher G. Parkin,Eric Renard,Banshi Saboo,Mauro Scharf,William V. Tamborlane,Stuart A. Weinzimer,Moshe Phillip

DOI: https://doi.org/10.2337/dc17-1600

2017-11-10

Diabetes Care

Abstract:Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.

endocrinology & metabolism
CGM-derived glucometrics in adults with type 1 diabetes when switching basal insulins.

Robbe De Groote,Eveline Lefever,Sara Charleer,Phebe Donné,Christophe De Block,Chantal Mathieu,Pieter Gillard

DOI: https://doi.org/10.1089/dia.2023.0616

2024-03-22

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Impact of HbA1c Testing at Point of Care on Diabetes Management.

Oliver Schnell,J Benjamin Crocker,Jianping Weng

DOI: https://doi.org/10.1177/1932296816678263

2016-01-01

Journal of Diabetes Science and Technology

Abstract:Diabetes is a highly prevalent disease also implicated in the development of several other serious complications like cardiovascular or renal disease. HbA1c testing is a vital step for effective diabetes management, however, given the low compliance to testing frequency and, commonly, a subsequent delay in the corresponding treatment modification, HbA1c at the point of care (POC) offers an opportunity for improvement of diabetes care. In this review, based on data from 1999 to 2016, we summarize the evidence supporting a further implementation of HbA1c testing at POC, discuss its limitations and propose recommendations for further development.
What Is the Tech Missing? Nutrition Reporting in Type 1 Diabetes

Nicole Lubasinski,Hood Thabit,Paul W. Nutter,Simon Harper

DOI: https://doi.org/10.3390/nu16111690

IF: 5.9

2024-05-30

Nutrients

Abstract:Introduction: Type 1 Diabetes (T1D) presents self-management challenges, requiring an additional 180 daily decisions to regulate blood glucose (BG) levels. Despite the potential, T1D-focused applications have a 43% attrition rate. This work delves into the willingness of people living with T1D (PwT1D) to use technology. Method: An online questionnaire investigated the current practices for carbohydrate estimation, nutritional tracking, and attitudes towards technology engagement, along with hypothetical scenarios and preferences regarding technology use. Results: Thirty-nine responses were collected from PwT1D (n = 33) and caregivers (n = 6). Nutrition reporting preferences varied, with 50% favoring 'type and scroll' while 30% preferred meal photographing. Concerning the timing of reporting, 33% reported before meals, 55% after, and 12% at a later time. Improved Time in Range (TIR) was a strong motivator for app use, with 78% expressing readiness to adjust insulin doses based on app suggestions for optimizing TIR. Meal descriptions varied; a single word was used in 42% of cases, 23% used a simple description (i.e., "Sunday dinner"), 30% included portion sizes, and 8% provided full recipes. Conclusion: PwT1D shows interest in using technology to reduce the diabetes burden when it leads to an improved TIR. For such technology to be ecologically valid, it needs to strike a balance between requiring minimal user input and providing significant data, such as meal tags, to ensure accurate blood glucose management without overwhelming users with reporting tasks.

nutrition & dietetics
Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use

David B. Sacks,M. Sue Kirkman,Randie R. Little

DOI: https://doi.org/10.2337/dci23-0040

2024-03-29

Diabetes Care

Abstract:Hemoglobin A1c (A1C) is widely used for the diagnosis and management of diabetes. Accurate measurement of A1C is necessary for optimal clinical value. Assay standardization has markedly improved the accuracy and consistency of A1C testing. Devices to measure A1C at point of care (POC) are commercially available, allowing rapid results when the patient is seen. In this review, we describe how standardization of A1C testing was achieved, leading to high-quality results in clinical laboratories. We address the use of POC A1C testing in clinical situations and summarize the advantages and disadvantages of POC A1C testing. We emphasize the importance of considering the limitations of these devices and following correct testing procedures to ensure that accurate A1C results are obtained for optimal care of patients.

endocrinology & metabolism
The Potential Impact of CGM Use on Diabetes-Related Attitudes and Behaviors in Adults with T2D: A Qualitative Investigation of the Patient Experience

Taylor Clark,William Polonsky,Emily Soriano

DOI: https://doi.org/10.1089/dia.2023.0612

2024-03-26

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Clinician-Reported Barriers and Needs for Implementation of Continuous Glucose Monitoring

Tristen Hall,Meredith K Warman,Tamara Oser,Melissa K Filippi,Brian Manning,Jennifer K Carroll,Donald E Nease Jr,Elizabeth W Staton,Sean Oser

DOI: https://doi.org/10.3122/jabfm.2024.240049R1

Abstract:Background: Continuous glucose monitoring (CGM) for patients with type 1 and type 2 diabetes is associated with improved clinical, behavioral, and psychosocial patient health outcomes and is part of the American Diabetes Association's Standards of Medical Care. CGM prescription often takes place in endocrinology practices, yet 50% of adults with type 1 diabetes and 90% of all people with type 2 diabetes receive their diabetes care in primary care settings. This study examined primary care clinicians' perceptions of barriers and resources needed to support CGM use in primary care. Methods: This qualitative study used semistructured interviews with primary care clinicians to understand barriers to CGM and resources needed to prescribe. Participants were recruited through practice-based research networks. Rapid qualitative analysis was used to summarize themes from interview findings. Results: We conducted interviews with 55 primary care clinicians across 21 states. Participants described CGM benefits for patients with varying levels of diabetes self-management and engagement. Major barriers to prescribing included lack of insurance coverage for CGM costs to patients, and time constraints. Participants identified resources needed to foster CGM prescribing, for example, clinician education, support staff, and EHR compatibility. Conclusion: Primary care clinicians face several challenges to prescribing CGM, but they are interested in learning more to help them offer it to their patients. This study reinforces the ongoing need for improved clinician education on CGM technology and continued expansion of insurance coverage for people with both type 1 and type 2 diabetes.
Automated insulin delivery system: A solution for moderate to high-risk Ramadan fasting in people living with type 1 diabetes

Cecilia Outenah,Khadijatou Ly Sall,Alfred Penfornis,amadou corlaie,Dured Dardari

DOI: https://doi.org/10.1089/dia.2024.0168

2024-06-19

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Mitigating Severe Hypoglycemia in Users of Advanced Diabetes Technologies: Impaired Awareness of Hypoglycemia and Unhelpful Hypoglycemia Beliefs as Targets for Interventions

Yu Kuei Lin,Wen Ye,Helen Rogers,Augustin Brooks,Elena Toschi,Dulmini Kariyawasam,Simon Heller,Nicole de Zoysa,Stephanie Amiel

DOI: https://doi.org/10.1089/dia.2024.0039

2024-04-26

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism

Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens

Standardizing Reporting of Glucose and Insulin Data for Patients on Multiple Daily Injections Using Connected Insulin Pens and Continuous Glucose Monitoring

Beyond Glucose Monitoring: Multianalyte Sensor Use in Diabetes.

Health literacy of patients using continuous glucose monitoring

Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research

923-P: Benefits of Electronic Consultations (E-Consults) in Improving Diabetes Care within a Safety-Net Health System

Response to: MiniMed 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias – Response to Inaccurate Allegations

Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Monitoring Technologies – Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control

Professional flash continuous glucose monitoring as a supplement to A1C in primary care

Assessing Patterns of CGM use and Metrics of Glycemic Control in T1D and T2D Patients in the Veterans Healthcare System: Integrating CGM Device Data with EHR Data

International Consensus on Use of Continuous Glucose Monitoring

CGM-derived glucometrics in adults with type 1 diabetes when switching basal insulins.

Impact of HbA1c Testing at Point of Care on Diabetes Management.

What Is the Tech Missing? Nutrition Reporting in Type 1 Diabetes

Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use

The Potential Impact of CGM Use on Diabetes-Related Attitudes and Behaviors in Adults with T2D: A Qualitative Investigation of the Patient Experience

Clinician-Reported Barriers and Needs for Implementation of Continuous Glucose Monitoring

Automated insulin delivery system: A solution for moderate to high-risk Ramadan fasting in people living with type 1 diabetes

Mitigating Severe Hypoglycemia in Users of Advanced Diabetes Technologies: Impaired Awareness of Hypoglycemia and Unhelpful Hypoglycemia Beliefs as Targets for Interventions